Loading stock data…
$3.83-0.13 (-3.28%)
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases.
Annexon, Inc. in the Healthcare sector is trading at $3.83 with a market capitalization of $796M. Wall Street consensus targets $15.43 (7 analysts), implying a +302.8% move over the next 12 months. The stock is currently 47% below its 52-week high of $7.18, remaining 28.0% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$57.23M↓ | -$46.05M↑ | -$50.26M↑ | -$57.02M↓ | -$51.73M |
| Net Income | -$55.35M↓ | -$44.14M↑ | -$48.26M↑ | -$54.92M↓ | -$49.16M |
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinica...